This trial looks at survival rates of bladder cancer patients who have never had BCG treatment, comparing two treatments to BCG.
- Bladder Cancer
1 Primary · 12 Secondary · Reporting Duration: Up to 5 years 2 months
Awards & Highlights
3 Treatment Groups
Treatment Group C: TAR-200 Alone
1 of 3
Treatment Group A: TAR-200 + Cetrelimab
1 of 3
Treatment Group B: Bacillus Calmette-Guerin (BCG) Vesiculture
1 of 3
1050 Total Participants · 3 Treatment Groups
Primary Treatment: Treatment Group C: TAR-200 Alone · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many facilities are currently hosting this research endeavor?
"This trial is presently seeking out patients from 40 diverse locations, including Little Rock, Duarte and Los Angeles. To lessen travel-related strain for participants, it is advised to enroll in the closest site available." - Anonymous Online Contributor
Has the Food and Drug Administration (FDA) granted authorization for Treatment Group A: TAR-200 + Cetrelimab?
"The combination of TAR-200 and Cetrelimab has been found to be relatively safe, with available data supporting their efficacy in a clinical setting. Therefore, our team at Power assigned this treatment program an overall score of 3." - Anonymous Online Contributor
Are there any vacancies to join this clinical trial?
"As indicated on clinicaltrials.gov, this research endeavour is no longer actively recruiting participants, having been posted in March of 2023 and last updated in late January of the same year. Despite not being an available opportunity for now, there are still 364 medical trials that require patient volunteers at present." - Anonymous Online Contributor